Skip to content

ESLAW

Estrella Immunopharma, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.08
+54.37%
Ask drillr

Income statement

MetricTTM2025202420242022
Revenue
Total Revenue—————
Cost of Revenue—————
Gross Profit—————
Operating Expenses
R&D Expense7.0M10.2M6.4M4.1M10.5M
SG&A Expense2.8M2.8M2.4M3.2M663.2K
General & Admin Expense2.8M2.8M2.4M3.2M663.2K
Selling & Marketing Expense—————
Other Expenses—————
Total Operating Expenses9.8M13.1M8.8M7.3M11.1M
Cost and Expenses9.8M13.1M8.8M7.3M11.1M
Operating Income (EBIT)(9.8M)(13.1M)(8.8M)(7.3M)(11.1M)
Non-Operating
Interest Income—————
Interest Expense—————
Net Interest Income—————
Other Non-Op Income/Expense(222.1K)————
Non-Operating Income (excl Interest)—————
EBT (Pre-Tax Income)(10.0M)(13.1M)(8.8M)(7.3M)(11.1M)
Income Tax Expense(25.00)838.001.7K1.6K—
Bottom Line
Net Income(10.0M)(13.1M)(8.8M)(7.3M)(11.1M)
Earnings from Cont. Ops(10.0M)(13.1M)(8.8M)(7.3M)(11.1M)
Earnings from Discont. Ops—————
Bottom Line Net Income(10.0M)(13.1M)(8.8M)(7.3M)(11.1M)
Per Share
Basic EPS($0.25)($0.35)($0.24)($0.21)($0.32)
Diluted EPS($0.25)($0.35)($0.24)($0.21)($0.32)
Revenue Per Share$0.00$0.00$0.00$0.00$0.00
Shares
Basic Shares Outstanding43.0M36.8M36.7M35.2M35.2M
Diluted Shares Outstanding43.0M36.8M36.7M35.2M35.2M
Profitability Metrics
EBITDA(9.8M)(13.1M)(8.8M)(7.3M)(11.1M)
D&A—————
EBIT(9.8M)(13.1M)(8.8M)(7.3M)(11.1M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026